226 related articles for article (PubMed ID: 24903780)
1. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
Froestl W; Muhs A; Pfeifer A
J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
[TBL] [Abstract][Full Text] [Related]
2. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.
Froestl W; Muhs A; Pfeifer A
J Alzheimers Dis; 2014; 41(4):961-1019. PubMed ID: 24898652
[TBL] [Abstract][Full Text] [Related]
3. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
Froestl W; Pfeifer A; Muhs A
J Alzheimers Dis; 2014; 42(4):1079-149. PubMed ID: 25061058
[TBL] [Abstract][Full Text] [Related]
4. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
Froestl W; Muhs A; Pfeifer A
J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
[TBL] [Abstract][Full Text] [Related]
5. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
Froestl W; Muhs A; Pfeifer A
J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
[TBL] [Abstract][Full Text] [Related]
6. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
Froestl W; Pfeifer A; Muhs A
J Alzheimers Dis; 2013; 34(1):1-114. PubMed ID: 23186990
[TBL] [Abstract][Full Text] [Related]
7. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
8. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
9. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
10. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
Harry RD; Zakzanis KK
Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
[TBL] [Abstract][Full Text] [Related]
11. Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms.
Drug Ther Bull; 2014 Jun; 52(6):69-72. PubMed ID: 24924683
[TBL] [Abstract][Full Text] [Related]
12. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
Stiles MM; Martin S; Persons RK
J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040
[No Abstract] [Full Text] [Related]
13. Donepezil in the treatment of patients with Alzheimer's disease.
Tsuno N
Expert Rev Neurother; 2009 May; 9(5):591-8. PubMed ID: 19402770
[TBL] [Abstract][Full Text] [Related]
14. Drugs influencing cognitive function.
Kuruvilla A; Devi V
Indian J Physiol Pharmacol; 1994 Oct; 38(4):241-51. PubMed ID: 7883287
[No Abstract] [Full Text] [Related]
15. Donepezil for Alzheimer's disease.
Benjamin B; Burns A
Expert Rev Neurother; 2007 Oct; 7(10):1243-9. PubMed ID: 17939763
[TBL] [Abstract][Full Text] [Related]
16. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
Strnad J; Bahro M
Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
[No Abstract] [Full Text] [Related]
17. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
Peskind ER
J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer's disease: the Osaki-Tajiri Project.
Meguro M; Kasai M; Akanuma K; Ishii H; Yamaguchi S; Meguro K
Age Ageing; 2008 Jul; 37(4):469-73. PubMed ID: 18515851
[No Abstract] [Full Text] [Related]
20. Cognitive enhancers for the treatment of neuropsychiatric disorders: clinical and preclinical investigations.
Kantak KM; Hofmann SG
Pharmacol Biochem Behav; 2011 Aug; 99(2):113-5. PubMed ID: 21316387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
